Scientific adviser
Simcere Bio-Pharmaceutical Technology Co., Ltd. (hereinafter referred to as“Simcere BioPharma”) was established in 2015, and is a wholly-owned subsidiary of Simcere Pharmaceutical Group. The Company is committed to pioneer in discovering, developing and commercializing innovative biologics drugs and challenging biosimilars for the treatment of cancer, immunological and infectious diseases. We are building a world class team with open mindset and cooperative attitude to become a leader in the biopharmaceutical industry in China and a key player in the global market.

After rapid expansion, Simcere BioPharma currently has 40 employees, including 13 with Ph.D. (9 with overseas experience) and 19 with M.S degree. Our management team, with rich global R&D experience in leading international research institutes and pharmaceutical industry, leads various research platforms including target validation, antibody engineering, in vitro cellular and molecular pharmacology, in vivo pharmacology, process development, protein production, quality analysis and translational medicine. Located in the same campus of the Ministry of Chinese Science and Technology approved 1st National Key Laboratory of Translational Medicine and Innovative Drug and Nanjing BioSciKin Innovation Platform, we seek to research and develop antibody, fusion protein and DNA vaccine drugs independently or collaboratively with domestic or global partners such as BMS, Amgen in the United States and Genexine in Korea, through in-licensing programs, joint ventures, co-development and commercialization, or external investment.

Currently, our portfolio includes 11 programs targeted towards indications in rheumatoid arthritis, ovarian cancer, colon cancer, NSCLC and pre-cervical cancer etc. One of our pipeline program was selected as “National Mega Innovative Program”. Our facilities include a newly built 1800m2 world class R&D laboratory equipped with many new state-of-the art equipment from the United States and Europe, 2000m2 animal center, 500m2 antibody production laboratory equipped with 100L and 500L single use bioreactors. In addition, a plant designed to meet FDA/EMA and CFDA cGMP standard for manufacturing recombinant protein and antibody drugs with full capacity of 4x2000L single use bioreactors is under construction.

We welcome passionate researcher fellows of any levels to join us.

© Copyright 2016 www.simcere.com All Rights Reserved.